China’s National Medical Products Administration Approves NUZYRA® (omadacycline) For The Treatment Of Bacterial Pneumonia And Skin Infections 

By GlobeNewswire BOSTON, Dec. 16, 2021 (GLOBE NEWSWIRE) — Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that the company’s partner in China, Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), received approval from the National Medical Products Administration (NMPA) of China of NUZYRA ® (omadacycline) for the treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI). Paratek commercially launched NUZYRA in the United States in February 2019. Paratek granted Zai Lab an exclusive license to develop, manufacture and commerc…

Read More